Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis

USRE46856E1 · kind E1 · reissue

Assignee

• Bayer Intellectual Property GmbH · DE

Inventors

• Martin F. Hentemann · Boulder, US
• Jill Wood · Hampton, US
• William Scott · Guilford, US
• Martin Michels
• Ann-Marie Campbell · Monroe, US
• Ann-Marie Bullion · Milford, US
• Bruce R. Rowley · New Hope, US
• Aniko Redman · Derby, US

Key dates

• Filing date: Jan 5, 2017
• Grant date: May 22, 2018
• Expiry date: Jan 5, 2037

Classification

• Technology area (CPC —): General

Abstract

This invention relates to novel 2,3-dihydroimidazo[1,2-c]quinazoline compounds, pharmaceutical compositions containing such compounds and the use of those compounds or compositions for phosphotidylinositol-3-kinase (PI3K) inhibition and treating diseases associated with phosphotidylinositol-3-kinase (PI3K) activity, in particular treating hyperproliferative and/or angiogenesis disorders, as a sole agent or in combination with other active ingredients.